Efficacy of salmeterol xinafoate in the treatment of COPD.

@article{Mahler1999EfficacyOS,
  title={Efficacy of salmeterol xinafoate in the treatment of COPD.},
  author={Donald A. Mahler and James F. Donohue and Robert A. Barbee and Michael David Goldman and Nicholas J. Gross and Michael E. Wisniewski and Steven W. Yancey and B A Zakes and Kathleen A Rickard and Wayne H Anderson},
  journal={Chest},
  year={1999},
  volume={115 4},
  pages={957-65}
}
STUDY OBJECTIVES To examine and compare the efficacy and safety of salmeterol xinafoate, a long-acting inhaled beta2-adrenergic agonist, with inhaled ipratropium bromide and inhaled placebo in patients with COPD. DESIGN A stratified, randomized, double-blind, double-dummy, placebo-controlled, parallel group clinical trial. SETTING Multiple sites at clinics and university medical centers throughout the United States. PATIENTS Four hundred eleven symptomatic patients with COPD with FEV1… CONTINUE READING
Highly Influential
This paper has highly influenced 14 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
163 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 163 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease

  • M Cazzola, MG Matera, G Santangelo
  • Pulm Pharmacol
  • 1994

Similar Papers

Loading similar papers…